{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:08:05Z","timestamp":1792462085879,"version":"4.5.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:sec id=\"ab-noi240074-4\"><jats:title>Importance<\/jats:title><jats:p>Huntington disease (HD) is characterized by motor, cognitive, and psychiatric decline. \u03b2-Blockers may play a therapeutic role by decreasing enhanced sympathetic tone in HD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi240074-5\"><jats:title>Objective<\/jats:title><jats:p>To evaluate the impact of \u03b2-blockers on the timing of motor diagnosis onset and progression of HD symptoms.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi240074-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This observational, longitudinal multicenter study used the Enroll-HD platform database (initiated September 2011 to present), including propensity score\u2013matched cohorts of patients with premanifest HD (preHD) and early motor-manifest HD (mmHD) who were either users or nonusers of \u03b2-blockers. Participants included patients with genetically confirmed preHD (n\u2009=\u20094683 eligible participants) or mmHD (n\u2009=\u20093024 eligible participants) who were taking a \u03b2-blocker and were matched to similar non\u2013\u03b2-blocker users.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi240074-7\"><jats:title>Exposure<\/jats:title><jats:p>Uninterrupted use of a \u03b2-blocker for more than 1 year.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi240074-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>For PreHD: risk of receiving a motor diagnosis of HD over time. For mmHD: progression rate of total motor score, total functional capacity score, and the symbol digit modalities test. Post hoc analyses were performed to test additional clarifying hypotheses after the primary analyses were completed.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi240074-9\"><jats:title>Results<\/jats:title><jats:p>This study included 174 preHD \u03b2-blocker users (59 males; 115 females) with a mean age of 46.4 (SD, 13.1) years and a mean cytosine-adenine guanine repeat length of 41.1 (SD, 2.4) who were well matched to 174 preHD non\u2013\u03b2-blocker users. The preHD \u03b2-blocker users showed a statistically significant reduction in the annualized hazard of receiving a motor diagnosis compared with nonusers (n\u2009=\u2009174) (hazard ratio, 0.66; 95% CI, 0.46-0.94; <jats:italic>P<\/jats:italic>\u2009=\u2009.02). There were 149 mmHD \u03b2-blocker users (86 males; 60 females) with a mean age of 58.9 (SD, 11.3) years and a mean cytosine-adenine guanine repeat length of 42.0 (SD, 2.3) matched to 149 mmHD non\u2013\u03b2-blocker users. The \u03b2-blocker users had a slower mean annualized worsening in total motor score  (mean difference [MD], \u22120.45; 95% CI, \u22120.85 to \u22120.06; q\u2009=\u20090.025), total functional capacity score (MD, 0.10; 95% CI, 0.02-0.18; q\u2009=\u20090.025), and symbol digit modalities test  (MD, 0.33; 95% CI, 0.10-0.56; q\u2009=\u20090.017) compared with matched nonusers.<\/jats:p><\/jats:sec><jats:sec id=\"ab-noi240074-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this study, \u03b2-blocker use was associated with delayed motor onset in preHD and reduced the rate of worsening of symptoms in mmHD. These findings demonstrated that \u03b2-blockers may have a therapeutic role in HD but further studies are required.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.4108","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T16:00:40Z","timestamp":1733155240000},"page":"85","source":"Crossref","is-referenced-by-count":7,"title":["\u03b2-Blocker Use and Delayed Onset and Progression of Huntington Disease"],"prefix":"10.1001","volume":"82","author":[{"given":"Jordan L.","family":"Schultz","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Carver College of Medicine at the University of Iowa, Iowa City"},{"name":"Department of Neurology, Carver College of Medicine at the University of Iowa, Iowa City"},{"name":"Department of Pharmacy Practice and Science, The University of Iowa College of Pharmacy, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Ogilvie","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Carver College of Medicine at the University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsay A.","family":"Harshman","sequence":"additional","affiliation":[{"name":"Stead Family Department of Pediatrics at the University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peg C.","family":"Nopoulos","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Carver College of Medicine at the University of Iowa, Iowa City"},{"name":"Department of Neurology, Carver College of Medicine at the University of Iowa, Iowa City"},{"name":"Stead Family Department of Pediatrics at the University of Iowa, Iowa City"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"noi240074r1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/ng0893-398","article-title":"The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington\u2019s disease.","volume":"4","author":"Andrew","year":"1993","journal-title":"Nat Genet"},{"issue":"6","key":"noi240074r2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes.","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"issue":"2","key":"noi240074r3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ajhg.2015.12.018","article-title":"The HTT CAG-expansion mutation determines age at death but not disease duration in Huntington disease.","volume":"98","author":"Keum","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"1","key":"noi240074r4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ajhg.2021.12.002","article-title":"Longer CAG repeat length is associated with shorter survival after disease onset in Huntington disease.","volume":"109","author":"Langbehn","year":"2022","journal-title":"Am J Hum Genet"},{"issue":"4","key":"noi240074r5","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/mds.28460","article-title":"Diabetes mellitus is associated with an earlier age of onset of Huntington\u2019s disease.","volume":"36","author":"Ogilvie","year":"2021","journal-title":"Mov Disord"},{"issue":"9","key":"noi240074r6","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1002\/mds.28062","article-title":"Hypertension is associated with an earlier age of onset of Huntington\u2019s disease.","volume":"35","author":"Schultz","year":"2020","journal-title":"Mov Disord"},{"issue":"9","key":"noi240074r7","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1212\/WNL.0000000000003661","article-title":"Substance abuse may hasten motor onset of Huntington disease: evaluating the Enroll-HD database.","volume":"88","author":"Schultz","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"noi240074r8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3233\/JHD-180287","article-title":"Human immunodeficiency virus infection in Huntington\u2019s disease is associated with an earlier age of symptom onset.","volume":"7","author":"Schultz","year":"2018","journal-title":"J Huntingtons Dis"},{"issue":"2","key":"noi240074r9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/mds.27591","article-title":"Statin use and delayed onset of Huntington\u2019s disease.","volume":"34","author":"Schultz","year":"2019","journal-title":"Mov Disord"},{"key":"noi240074r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2021.102775","article-title":"Autonomic dysregulation as an early pathologic feature of Huntington disease.","volume":"231","author":"Schultz","year":"2021","journal-title":"Auton Neurosci"},{"issue":"6","key":"noi240074r11","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1136\/jnnp.72.6.726","article-title":"Autonomic nervous system function in Huntington\u2019s disease.","volume":"72","author":"Andrich","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"noi240074r12","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/j.1600-0404.2009.01251.x","article-title":"Autonomic dysfunction in presymptomatic and early symptomatic Huntington\u2019s disease.","volume":"121","author":"Kobal","year":"2010","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"noi240074r13","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac253","article-title":"Autonomic changes in Huntington\u2019s disease correlate with altered central autonomic network connectivity.","volume":"4","author":"Schultz","year":"2022","journal-title":"Brain Commun"},{"issue":"2","key":"noi240074r14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mdc3.12388","article-title":"Data analytics from Enroll-HD, a global clinical research platform for Huntington\u2019s disease.","volume":"4","author":"Landwehrmeyer","year":"2016","journal-title":"Mov Disord Clin Pract"},{"issue":"2","key":"noi240074r15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington\u2019s Disease Rating Scale: reliability and consistency.","volume":"11","author":"Huntington Study Group","year":"1996","journal-title":"Mov Disord"},{"key":"noi240074r16","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29251","article-title":"Longitudinal clinical and biological characteristics in juvenile-onset Huntington\u2019s disease.","author":"Schultz","year":"2022","journal-title":"Mov Disord"},{"issue":"7","key":"noi240074r17","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","article-title":"A biological classification of Huntington\u2019s disease: the Integrated Staging System.","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol"},{"issue":"8","key":"noi240074r18","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference.","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"issue":"1","key":"noi240074r19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate\u2014a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"key":"noi240074r21","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.parkreldis.2016.09.004","article-title":"Propranolol therapy for Tardive dyskinesia: a retrospective examination.","volume":"32","author":"Hatcher-Martin","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"noi240074r20","unstructured":"Enroll HD. Homepage. Accessed October 28, 2024. https:\/\/enroll-hd.org\/"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2827461\/jamaneurology_schultz_2024_oi_240074_1735932279.94669.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T16:02:05Z","timestamp":1736784125000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2827461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.4108","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}